Marker Therapeutics (MRKR) Change in Accured Expenses (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Change in Accured Expenses data on file, last reported at $1.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $1.0 million, up 197.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 844.75% YoY), and the FY2025 annual result was -$1.7 million, down 19624.03% from the prior year.
• Change in Accured Expenses climbed to $1.0 million in Q1 2026 per MRKR's latest filing, from -$1.6 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.9 million in Q2 2022 and troughed at -$4.0 million in Q1 2022.
• A 5-year average of -$161094.9 and a median of $170885.0 in 2023 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 257.47% in 2024 and fell as far as 1546.08% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$1.0 million in 2022, then retreated by 5.41% to -$1.1 million in 2023, then soared by 140.04% to $434978.0 in 2024, then sank by 472.71% to -$1.6 million in 2025, then jumped by 161.76% to $1.0 million in 2026.
• Business Quant data shows MRKR's Change in Accured Expenses at $1.0 million in Q1 2026, -$1.6 million in Q4 2025, and $964562.0 in Q3 2025.